Literature DB >> 23122930

Long-term results of liver resection for hepatocellular carcinoma in noncirrhotic liver.

Wladimir Faber1, Siamak Sharafi, Martin Stockmann, Timm Denecke, Bruno Sinn, Gero Puhl, Marcus Bahra, Maciej B Malinowski, Peter Neuhaus, Daniel Seehofer.   

Abstract

BACKGROUND: Hepatocellular carcinoma (HCC) is among the most common malignant neoplasms worldwide. Only few data on HCC in noncirrhotic livers without viral hepatitis in Western countries are available. The purpose of this study was to define the outcomes and potential prognostic factors associated with survival after hepatic resection in patients with HCC in the absence of liver cirrhosis and hepatitis B or C infection. PATIENTS AND METHODS: From January 2000 to September 2010, 148 patients without liver cirrhosis and without extrahepatic metastases underwent curative hepatic resection for HCC at the Surgical Department of the Charité, Campus Virchow Klinikum. The outcomes of these patients were retrospectively reviewed. Patients with cirrhosis or severe fibrosis, fibrolamellar HCC, and those positive for hepatitis B or C were excluded.
RESULTS: The cumulative 1-, 3-, 5-, and 7-year survival rates were 75.4%, 54.7%, 38.9%, and 31.8%, respectively. The 1-, 3-, 5-, and 7-year disease-free survival rates were 60.3%, 38.0%, 29.1%, and 18.1%, respectively. In the multivariate analysis, cumulative survival was decreased by patient age, increased operative time, increased preoperative serum gamma-glutamyl transferase (GGT), and tumor stage. In the subgroup with unifocal neoplasms, N0 and R0 status, tumor size >10 cm, and tumor differentiation were highly predictive of lesser survival. Unfavorable survival was observed in patients with multifocal neoplasms, tumor size >10 cm, and/or poor tumor differentiation.
CONCLUSION: The current TNM staging system is stratified for survival and recurrence. Extension of the current TNM staging system by grading and more exact differentiation of tumor size may increase its prognostic accuracy for predicting outcome. Preoperative increased serum GGT level could be a new poor prognostic factor.
Copyright © 2013 Mosby, Inc. All rights reserved.

Entities:  

Mesh:

Year:  2012        PMID: 23122930     DOI: 10.1016/j.surg.2012.09.015

Source DB:  PubMed          Journal:  Surgery        ISSN: 0039-6060            Impact factor:   3.982


  20 in total

1.  Model based on γ-glutamyltransferase and alkaline phosphatase for hepatocellular carcinoma prognosis.

Authors:  Xin-Sen Xu; Yong Wan; Si-Dong Song; Wei Chen; Run-Chen Miao; Yan-Yan Zhou; Ling-Qiang Zhang; Kai Qu; Si-Nan Liu; Yue-Lang Zhang; Ya-Feng Dong; Chang Liu
Journal:  World J Gastroenterol       Date:  2014-08-21       Impact factor: 5.742

2.  Outcomes Following Resection of Hepatocellular Carcinoma in the Absence of Cirrhosis.

Authors:  Richard H Lewis; Evan S Glazer; David M Bittenbinder; Thomas O'Brien; Jeremiah L Deneve; David Shibata; Stephen W Behrman; Jason M Vanatta; Sanjaya K Satapathy; Paxton V Dickson
Journal:  J Gastrointest Cancer       Date:  2019-12

3.  Survival Benefit of Locoregional Treatment for Hepatocellular Carcinoma with Advanced Liver Cirrhosis.

Authors:  Satoshi Kitai; Masatoshi Kudo; Naoshi Nishida; Namiki Izumi; Michiie Sakamoto; Yutaka Matsuyama; Takafumi Ichida; Osamu Nakashima; Osamu Matsui; Yonson Ku; Norihiro Kokudo; Masatoshi Makuuchi
Journal:  Liver Cancer       Date:  2016-05-03       Impact factor: 11.740

4.  Prognostic factors of disease-free and overall survival in patients with hepatocellular carcinoma undergoing partial hepatectomy in curative intent.

Authors:  Georg Lurje; Jan Bednarsch; Zoltan Czigany; Iakovos Amygdalos; Franziska Meister; Wenzel Schöning; Tom Florian Ulmer; Martin Foerster; Cornelis Dejong; Ulf Peter Neumann
Journal:  Langenbecks Arch Surg       Date:  2018-09-28       Impact factor: 3.445

Review 5.  [Operative therapy of hepatocellular carcinoma].

Authors:  S A Farkas; H J Schlitt
Journal:  Radiologe       Date:  2014-07       Impact factor: 0.635

Review 6.  [Resection and transplantation for hepatocellular carcinoma and intrahepatic cholangiocarcinoma].

Authors:  Daniel Seehofer; Robert Sucher; Timm Denecke
Journal:  Radiologe       Date:  2022-01-26       Impact factor: 0.635

Review 7.  Extracellular Vesicles and Hepatocellular Carcinoma: Opportunities and Challenges.

Authors:  Juan Wang; Xiaoya Wang; Xintong Zhang; Tingting Shao; Yanmei Luo; Wei Wang; Yunwei Han
Journal:  Front Oncol       Date:  2022-05-25       Impact factor: 5.738

Review 8.  Hepatocellular carcinoma: From clinical practice to evidence-based treatment protocols.

Authors:  Danijel Galun; Dragan Basaric; Marinko Zuvela; Predrag Bulajic; Aleksandar Bogdanovic; Nemanja Bidzic; Miroslav Milicevic
Journal:  World J Hepatol       Date:  2015-09-18

9.  Tumor grade may be used to select patients with multifocal hepatocellular carcinoma for resection.

Authors:  Samantha M Ruff; Luke D Rothermel; Laurence P Diggs; Michael M Wach; Reed I Ayabe; Sean P Martin; David Boulware; Daniel Anaya; Jeremy L Davis; John E Mullinax; Jonathan M Hernandez
Journal:  HPB (Oxford)       Date:  2019-11-13       Impact factor: 3.647

10.  High Levels of Gamma-Glutamyl Transferase and Indocyanine Green Retention Rate at 15 min as Preoperative Predictors of Tumor Recurrence in Patients With Hepatocellular Carcinoma.

Authors:  Peipei Song; Yoshinori Inagaki; Zhigang Wang; Kiyoshi Hasegawa; Yoshihiro Sakamoto; Junichi Arita; Wei Tang; Norihiro Kokudo
Journal:  Medicine (Baltimore)       Date:  2015-05       Impact factor: 1.889

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.